ADC

CMC GLP

2023 **32**



Overview of the natural function of antibodies[1]

VHH

VHH ELISA

B

B B B Ig , , B

- 5-9
- B
- 1
- BCR
- 5-6

B



Nectin-4 Mouse Serum Titer



Nectin-4 (4-1) Sequencing (Top20)



Nectin-4 (4-6) Sequencing (Top20)



Nectin-4 (4-1) Sorting Single B Cell



Nectin-4 (4-6) Sorting Single B Cell



Raji cells were mixed with human PBMCs, and different doses of Rituximab was added to induce ADCC, the killing of raji cells were detected through FACS(CFSE labeling of raji).



Raji cells were mixed with human AB serum, and different doses of Rituximab was added to induce CDC, the killing of raji cells were detected through FACS(PI staining of raji).



B cells were treated with Teliacicept and induced with Baff for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.



T cells were treated with compound A and induced with ICOSL for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.

- A/IgG1 CD3/LPS PBMC 25 Luminex TNFα .

- ICH IL-2 IL-6 IL-10 IFN-γ TNF-α PBMC 3 ELISA Luminex CBA MSD OKT3

-



CMC

DOE

2022 2 LQ036—— IL-4Rα ( ) IND CDE LQ036
LQ036
LQ036 LQ036 NMPA TGA

: CD3+ Bispecific Antibody



- **Animals:**
  Female NOG mice
- **Tumor Cells:**
  Tumor mixed hPBMC (1:1) with 50% Matrigel, SC
- **PBMC:**
  injected before tumor cells inoculation
- **Treatment:**
  Bispecific antibody

Mean Tumor Volum (mm^3) Day 14

Group	TV	$\%TGI_{TV}$	Value
Vehicle	1639.53	/	/
An body	340.90	90.38	<0.001

/ PK

: Pharmacokinetics of YYB-101 in cynomolgus monkeys

YYB-101 10 mg/kg T_{max} 2

Pharmacokinetic profile of YYB-101 in cynomolgus monkeys[4]

YYB-101 50mg/kg 29 85

1

I (NCT02499224)

Toxicokinetic parameters on days 1 and 22 following intravenous infusion of YYB-101 at 10, 50, or 200 mg/kg perday in cynomolgus monkeys[4]

BAT6021 BAT6005

2021 9 BAT6021 BAT6005 BAT6021 BAT6005
TIGIT BAT6021 BAT6005

BAT7104

2021 10 PD-L1/CD47 BAT7104 BAT7104
PD-L1/CD47 PD-1/PD-L1 CD47/SIRP-α BAT7104
GLP BAT7104
BAT7104

JYB1904

2022 5 IgE JYB1904 JYB1904 IgE
JYB1904
GLP JYB1904

CC312

2022 6 CD19/CD3/CD28 CC312 IND FDA
CD28 CC312
CC312 GLP

GT90008

2022 10 PD-L1/TGF-β (GT90008) GT90008 PD-L1/TGF-β PD-L1
TGF-βR2 GT90008 /
GLP

HCW9218

2022 10 HCW Biologics Inc. HCW9218 FDA HCW9218
TGF-β II IL-15/IL-15 α NK $CD8^+$ T
HCW GLP
HCW9218
SEND HCW9218 FDA

:

[1] Ivana Spasevska. An outlook on bispecific antibodies: Methods of production and therapeutic benefits.

[2] Abdullah F U H Saeed, et al. Antibody Engineering for Pursuing a Healthier Future. Front Microbiol. 2017 Mar 28;8:495. doi: 10.3389/fmicb.2017.00495.